CareDx, Inc. (NASDAQ:CDNA) Stock Has Consensus Target Price of $70.33 According to Analysts

Shares of CareDx, Inc. (NASDAQ:CDNA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $70.33.

Several research analysts have recently issued reports on CDNA shares. Zacks Research upgraded shares of CareDx from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 5th. Wall Street Zen downgraded CareDx from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Weiss Ratings raised shares of CareDx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Craig Hallum upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research note on Monday, August 3rd. Finally, HC Wainwright reiterated a “neutral” rating and set a $46.00 price objective on shares of CareDx in a research report on Friday, July 31st.

Read Our Latest Research Report on CareDx

CareDx Price Performance

NASDAQ:CDNA opened at $74.44 on Thursday. The firm has a market capitalization of $3.91 billion, a P/E ratio of 31.15 and a beta of 2.51. CareDx has a one year low of $15.56 and a one year high of $90.87. The company’s 50-day simple moving average is $67.77 and its 200 day simple moving average is $37.51.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The firm had revenue of $139.36 million for the quarter, compared to analysts’ expectations of $121.96 million. During the same period in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was up 39.3% compared to the same quarter last year. On average, equities research analysts expect that CareDx will post 1.00 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael Goldberg sold 13,800 shares of CareDx stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $79.15, for a total transaction of $1,092,270.00. Following the sale, the director owned 48,526 shares in the company, valued at $3,840,832.90. This trade represents a 22.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Keith Kennedy sold 2,097 shares of CareDx stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $79.29, for a total transaction of $166,271.13. Following the completion of the sale, the chief financial officer owned 199,147 shares in the company, valued at approximately $15,790,365.63. This represents a 1.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,143 shares of company stock worth $6,475,506 over the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CareDx

Large investors have recently made changes to their positions in the company. Nykredit A S bought a new stake in CareDx in the second quarter worth $25,000. Integrated Wealth Concepts LLC bought a new position in shares of CareDx in the 2nd quarter valued at about $29,000. Reyes Financial Architecture Inc. purchased a new position in CareDx in the third quarter worth about $50,000. Signaturefd LLC bought a new stake in CareDx during the third quarter worth approximately $51,000. Finally, Global Retirement Partners LLC increased its position in shares of CareDx by 11,955.6% during the 3rd quarter. Global Retirement Partners LLC now owns 1,085 shares of the company’s stock valued at $71,000 after purchasing an additional 1,076 shares during the last quarter.

About CareDx

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Further Reading

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.